Herrmann Ken
SEC Form 4 insider trading activity
Herrmann Ken has filed 2 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jul 22, 2026.
On the most recent filing, Herrmann Ken is listed as Director at Aktis Oncology, Inc. Inside the rolling window, Herrmann Ken reported no open-market purchases and 2 open-market sales totaling $197K in AKTS. The largest disclosed transaction in the window is a sale of 4,856 AKTS shares on Jul 20, 2026, worth $119K.
Companies traded
Other insiders at AKTS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$197K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Herrmann Ken made?
Herrmann Ken has filed 2 SEC Form 4 filings (6 transaction rows) across 1 company since 2026.
Which companies does Herrmann Ken trade?
Herrmann Ken has filed SEC Form 4 disclosures for 1 company, including AKTS.
When was Herrmann Ken's most recent SEC Form 4 filing?
Herrmann Ken's most recent SEC Form 4 filing on Tracefour is dated Jul 22, 2026.
What is Herrmann Ken's total buy and sell value in the current window?
Inside the rolling retention window, Herrmann Ken bought $0 and sold $197K based on SEC Form 4 filings.
What was Herrmann Ken's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,856 AKTS shares on 2026-07-20, worth $119K, per SEC Form 4 filings.